Lenira-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea associated with allergic responses. Montelukast, a leukotriene receptor antagonist, blocks the action of cysteinyl leukotrienes, which are inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, making it effective in controlling asthma symptoms and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from both immediate and delayed allergic symptoms. Lenira-M is typically administered once daily, with or without food, and is well-tolerated in both adult and pediatric populations. It is important to adhere to prescribed dosages and consult a healthcare professional before use, especially in patients with hepatic or renal impairment. Common side effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances, though these are generally mild and transient. Lenira-M Tablet offers an effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist therapy.